May 2012 Private and Confidential This document is intended exclusively for the confidential use of its recipients, based on their recognition and acceptance of the confidentiality of the same. The reproduction of this information, in whole or in part, is totally forbidden, as well as its communication to third parties without the prior express consent of the issuer. Confidential: For intended recipient use only Confidential: For intended recipient use only 1
INDEX 1. COMPANY OVERVIEW 2. AB-FUNCTIONAL INGREDIENTS 3. AB-GENOTYPING 4. QUANTUM - R&D SERVICES Confidential: For intended recipient use only Confidential: For intended recipient use only 2
COMPANY OVERVIEW - OUR MISSION & VALUES AB-BIOTICS strives to improve health by developing products and providing Mission services that help support healthy living and prevent disease. AB-BIOTICS aspires to set a standard in the European biotechnology Vision industry for both value and profitability. History 2004 2011 2008 •Company Founded at •Capital Increase – €4,3M •1st Financing Round: Universitat Autonoma •Acquisition of Quantum Experimental Business Angels – € 1M Barcelona •€5,0M Turnover 2010 2012 •Financing Round: Public •International Expansion Trading € 3,5M (US, BR) • € 3,6M Turnover Confidential: For intended recipient use only Confidential: For intended recipient use only 3
COMPANY OVERVIEW – BUSINESS AREAS R&D SERVICES & Project Management R&D projects for companies. Main clients belong to the Food Functional and Food supplements. Quantum Experimental :CRO, regulatory, analysis, and industrial. Historic 5 years in operation and constant growth. In company R&D for development of functional ingredients, Company subsidiary dedicated to the development of advanced mainly probiotics for application in functional foods and food genetic tools for pharmacogenetics (SNP, CNV) The company has appropriate human and technical resources for supplements . conducting genetic analysis. A balanced risk portfolio: Focus on areas with clearest competitive advantage: - PROFIT POTENTIAL + AB-Functional Ingredients & AB-Genotyping - RISK + Confidential: For intended recipient use only Confidential: For intended recipient use only 4
AB-FUNCTIONAL INGREDIENTS 1. COMPANY OVERVIEW 2. AB-FUNCTIONAL INGREDIENTS 3. AB-GENOTYPING 4. QUANTUM - R&D SERVICES Confidential: For intended recipient use only Confidential: For intended recipient use only 5
AB-FUNCTIONAL INGREDIENTS - MARKET OVERVIEW Market Projections Competitive Advantage AB-Biotics strain bank has over 550 different strains with highly unique characteristics. FF= Fortified/Functional, VDS=Vitamin, Dietary, Supplement* Probiotics have been a major growth driver within FF AB-Biotic´s clear strain definition, unique source food, while probiotic supplements have been among the hypothesis , and large strain bank provides a clear most dynamic products within the global VDS market. * competitive differentiation in probiotics. *Source: Euromonitor Oct 2010 Confidential: For intended recipient use only Confidential: For intended recipient use only 6
AB-FUNCTIONAL INGREDIENTS - AB-LIFE The Market Cardiovascular disease is the world´s leading cause of death (49% in Spain).* High cholesterol increases risk of cardiovascular disease. Current treatments only target one of the two types of cholesterol (endogenous, dietary). Additionally, adverse hepatic and intestinal reactions arise at high doses. AB-LIFE, a probiotic , significantly lowers both types of The Product cholesterol and has no adverse reactions at high doses. It can be delivered as food ingredient or supplement. Patented product in PCT phase of IP protection entering national phase in the next 6-8 months. Spanish ** Recent license agreements have been reached in Recent News Brazil, Spain, Hungary and Slovenia for supplements. Negotiating with MNCs for world-wide license (food). English*** •Source: WHO 2010 **http://www.youtube.com/user/ABBIOTICS#p/a/u/2/fv3IMsqv19o *** http://www.youtube.com/user/ABBIOTICS#p/a/u/1/kkvjSCbA0X8 Confidential: For intended recipient use only Confidential: For intended recipient use only 7
AB-FUNCTIONAL INGREDIENTS – IBS - 3.1 The Market IBS, characterized by abdominal pain, discomfort, bloating and altered intestinal motility and transit, and affects between 10 - 15% of the population* . Existing treatments are extremely limited by effect and carry significant side effects. Pharmacological treatment is limited in most countries. IBS 3.1, a probiotic, achieves a global improvement in The Product Quality of Life of afflicted patients, according to initial results from a multicentric clinical trial. Patented product in PCT phase of IP protection, entering national phase by July 2012. Current clinical trials will conclude by December, English** Recent News and clinical trials in the US begin in Q1 2012. Presented at Biowashington 2011. * Source: Quigley EM et al, July 2006 Aliment. Pharmacol. Ther ** http://www.youtube.com/user/ABBIOTICS#p/a/u/0/U4Gt2X_rpos Confidential: For intended recipient use only Confidential: For intended recipient use only 8
AB-FUNCTIONAL INGREDIENTS - AB-FORTIS The Market Iron deficiency in children, whether due to diet or absorption, can lead to lower infection resistance and impaired pyschomotor and cognitive development* . Current fortification solutions have issues with iron oxidation, leading to a false metallic taste and lower shelf-life stability. *SAC = School-Age-Children Impact AB-FORTIS can deliver 100% of the iron CDR with no The Product oxidation in yoghurt, milk, or meat, and can delivered as a food supplement. Patented product entering national phase of IP protection. 11 health claims approved by EFSA . Spanish ** Over the next 2-12 months, examinations for national Recent News phase of protection will begin in 32 different countries . Negotiating with MNCs for world-wide license . English *** * Source: Kigangou, 2005, Ped. Res. 731 ** http://www.youtube.com/user/ABBIOTICS#p/a/u/0/wUx0Y1yDLxI *** http://www.youtube.com/user/ABBIOTICS#p/a/u/1/aQHRX7Lt1A8 Confidential: For intended recipient use only Confidential: For intended recipient use only 9
AB-GENOTYPING 1. COMPANY OVERVIEW 2. AB-FUNCTIONAL INGREDIENTS 3. AB-GENOTYPING 4. QUANTUM - R&D SERVICES Confidential: For intended recipient use only Confidential: For intended recipient use only 10
AB-GENOTYPING - MARKET OVERVIEW Personalized Medicine and Pharmacogenetics “It is not the analysis of disease genetic risk factors that shoes the most immediate promise for human health, but the application of genetic information to permit safer and more efficacious use of drugs.” – Caplan A., What Will Drive Genomics Over the Next 10 Years, Science 2011 “ The evolution of personalized medicine will change the healthcare industry. In the process, it is likely that several “gamechangers” will emerge—aspects of new technology that will result in significant commercial or social impacts.” - DC-based research and consulting firm Social Technologies “Industry consensus is that pharmacogenomics – that is, combination diagnostic and pharmaceutical products – will be part of mainstream medicine within 10 years.” - PWC Neuropsychiatry Neurofarmagen product launched since January 2010. % Inefficient % Prevalence Treatment Depression 10% 80% Epilepsy, Schizophrenia, Bipolar 1% 20-30% Cancer Oncofarmagen pipeline product.. Confidential: For intended recipient use only Confidential: For intended recipient use only 11
AB-GENOTYPING - PHARMACOGENETICS CURRENT PERSONALIZED MEDICINE THERAPEUTIC MODEL Same diagnostic Same diagnostic + Genetic test Test benefits Same treatment 1. Decreased adverse reactions Increase dose drug 2. Safer election of drugs Standard dose 3. Better treatment compliance 4. Increased probability of therapeutic Dose reduction success Drastic reduction in dose or 5. Reduced costs for Health Care drug change System Herceptin’s Clinical Trial (Roche) Aclara Bioscience (Monogram Bioscience). Business Insights ltd. Confidential: For intended recipient use only Confidential: For intended recipient use only 12
AB-GENOTYPING - NEUROFARMAGEN 2/3 patients significantly improves their quality of life. No side effects & higher efficacy. Fast stabilization for patients with epilepsy, clinical depression, bipolar syndrome and schizophrenia. NEUROPHARMAGEN V.2.1 compiles information for a total of 39 drugs Number of tested drugs 39 Quality controls 48 Number of genetic variations 98 Number of genes analyzed 53 Confidential: For intended recipient use only Confidential: For intended recipient use only 13
QUANTUM AND R&D SERVICES 1. COMPANY OVERVIEW 2. AB-FUNCTIONAL INGREDIENTS 3. AB-GENOTYPING 4. QUANTUM - R&D SERVICES Confidential: For intended recipient use only Confidential: For intended recipient use only 14
Recommend
More recommend
